Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.InVasc Therapeutics, a developer of drugs to mitigate risks associated with chronic kidney and cardiometabolic diseases, has started an active-controlled, double-blind, multi-center and randomized proof of concept (POC) Phase IIa trial to evaluate INV-144.
Subscribe to our email newsletter
InVasc’s INV-144 is a combination drug of losartan and alpha Lipoic Acid (ALA), which is used to slow down the progression of chronic kidney disease (CKD) in patients with hypertensive diabetic patients.
Earlier, INV-144’s sister compound INV-141 showed positive results and demonstrated reduction reduction of proteinuria in the same patient population.
InVasc CEO William Johnston said the study allows them to compare INV-144 to an early version of the drug, INV-141, that previously demonstrated statistical significance in similar patients.
"We anticipate that this study will provide the data needed to move forward with additional studies designed to optimize this combination drug," Johnston said.